Type Public company Industry Cancer diagnostics Founded 2001 | Traded as NZX: PEB Headquarters New Zealand | |
Area served New Zealand, Australia, Spain, United States of America Key people David Darling (Group CEO) and Jackie Walker (CEO of Pacific Edge Diagnostics USA) Products CxBladder Suite of bladder cancer diagnostics tools Stock price PEB (NZE) NZ$ 0.57 0.00 (0.00%)20 Mar, 12:23 PM GMT+13 - Disclaimer Subsidiaries Pacific Edge Diagnostics New Zealand Limited | ||
Pacific Edge Limited is a cancer diagnostics New Zealand company that offers a genetic biomarker based suite of bladder cancer diagnostic tools. The company has offices in Hershey, Pennsylvania, and its head office in Dunedin, New Zealand. Pacific Edge is listed on the New Zealand NZX main board stock exchange under ticker code PEB, and forms part of the NZX 50 Index.
Contents
History
Established in August 2001, Pacific Edge uses genetic biomarkers in urine to detect the presence of cancer. They market themselves as being a third less expensive than other diagnostic tools.
They provide a diagnostic service through their facilities in New Zealand and the United States as well as selected partners in Europe and Australia.
The firm is listed on the New Zealand NZX index. They have had a number of capital raises, most recently in 2013 and 2015 to pursue commercialisation of their diagnostic tests in the USA.
Products
Pacific Edge's suite of tests for bladder cancer are called CxBladder, with specialist sub-type products to detect cancerous cells and provide triage for clinicians and oncologists. Their tests samples are non-invasive urine test based on RNA and protein assays, with high sensitivity and earlier detection than other forms of bladder cancer diagnostics like cytology.
Awards
Pacific Edge has won a number of awards, including